Galaxy Diagnostics was founded by academic researchers and continues to lead with science that’s transparent, published, and reproducible. We believe diagnostics must be grounded in data that providers can trust and that trust starts with evidence that’s available, validated, and clinically useful.
Digital PCR application in infectious disease diagnostics
Culture-based detection and clinical relevance of Bartonella
Diagnostic strategies for vector-borne pathogens in chronic cases
All methods rigorously validated to ensure reproducibility, trust, and clinical utility
Peer-reviewed science informs every step of test development
Transparent methodology is available to providers on request
Galaxy’s research leadership includes:
We provide pathogen testing and other diagnostic testing services for clinical trials, epidemiological studies, basic research initiatives and new diagnostic test development, as requested by a variety of stakeholders including industry, civilian or military governmental agencies, academic and non-profit organizations. We offer both CLIA-validated molecular and serological assays testing for a growing range of zoonotic, vector-borne infectious agents, including Bartonella spp, Borrelia spp.
Galaxy Diagnostics offers pathogen testing services to research collaborators at universities and other biotech companies. Some of our recent research and testing partners include: Bayer Animal Health, Idexx Reference Labs, Focus on Lyme, Duke University, University of Minnesota, University of Washington’s Center for One Health Research, One Medicine Institute, a few drug development companies, and many others.
If you or your organization is interested in collaborating on a project, please e-mail us at [email protected], for more information.
Galaxy Diagnostics partners with researchers across the country, offering advanced pathogen testing services to accelerate clinical trials, epidemiological studies, and innovative diagnostic developments.
